Since you weren't kind enough to post the actual data
The Phase 3 TRIUMPH clinical program is ongoing and expected to conclude in 2026 with a couple thousand participants. Thus far:
24.2% mean weight reduction after 48 weeks (Tirz is 22.5 over 72 weeks)
Greater liver fat reduction over Tirz (82% reduction in 24 weeks with max dose) plus normalization of liver fat after 48 weeks for 85% of participants.
Reduction in triglycerides by 40%
Lowered apoC-III, which improves lipid metabolism, triglycerides specifically.
Interestingly, tirzepatide showed slightly greater reductions in HbA1c (2.4% vs. 2.02%) but that may be within the margin of error.
What seems most significant is the weight reduction and liver fat reduction over tirzepatide. Of note is the fact that these trials are run on folks with obesity, and a large portion on people with established ASCVD. Applicability to body builders is going to vary.